↓ Skip to main content

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter
5 X users
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
69 Mendeley